Genentech reviews

Corporate politics have split company into competing factions with different priorities that increase inefficiencies and drug development timelines/costs, maintain divisions between Roche and GNE, and increase bureaucratic processes instead of focusing on medicine and patients. Too many changes based on cost-cutting leading to 'brain-drain' of excellent people, some of these changes unnecessary such as change in cafeteria vendor so food is now awful. Other necessary changes still have not occurred including one email or calendar client or other software to minimize system errors and inefficiencies. Can't trust management to keep to promises or be transparent on decision-making, increase in management layers have increased the number of people focused on politics rather than science & who create barriers for the people beneath them doing the work to develop medicine. Unfairness in promotions have increased as middle management gather supporters around them in a time of flux. People in the same department still have not integrated titles so Roche employees' may be reporting to GNE people with a lower title or have been mapped to a much lower level than justified. Unfairness in compensation also as bonuses are also scheduled to match Roche's to be much lower for GNE employees but salaries will not be raised to match Roche's so GNE employees will have lower compensation overall than Roche counterparts. Lots more changes still to come make this an awful company to work for in the next few years.

Jobs are not secure, Swiss owners don't care about or respect US employees. Company only cares about making money, not helping patients or medical research.